
Opinion|Videos|June 23, 2025
Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging
Panelists discuss how the new PET technology could identify lymph node involvement not visible on conventional imaging, providing actionable information for surgical planning or indicating the need for systemic therapy rather than surgery alone.
Advertisement
Episodes in this series

Lymph Node Management and Molecular Imaging
Main Discussion Topics:
- The current approach typically limits lymph node dissection to radiographically evident disease.
- Molecular imaging could identify nodal disease missed by conventional imaging.
- Detection of nodal disease by molecular imaging would be actionable.
- Could influence surgical planning or shift patients toward systemic therapy approaches
Key Points for Physicians:
- Neither expert routinely performs lymph node dissection without radiographic indication.
- A positive node on molecular imaging would likely change management.
- Options include targeted lymph node dissection or initiation of systemic therapy.
- Improved node detection could help homogenize treatment groups in clinical trials.
Notable Insights:
Nodal disease detected by molecular imaging is considered biologically significant and likely indicates systemic disease requiring more than surgery alone.
Clinical Significance:
Molecular imaging could fundamentally change nodal staging and management decisions, potentially moving patients from surgery-first approaches to systemic therapy.
Advertisement
Related to this article

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
The UroOnc Minute: The Role of Language in Cancer Care, With Jessica Rett, PhD
5


